Large-scale testing (Phase 3)Not Yet RecruitingNCT06380348
What this trial is testing
JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations
Who this might be right for
Local Advanced or Metastatic NSCLC
Shanghai JMT-Bio Inc. 398